Table 2. Responses of patients with... | American Society of Hematology

Table 2.

Responses of patients with CP-CML achieving cytogenetic response after TKI

Cumulative response	No ACAs (n = 473)		CCA/Ph⁻(n = 54)		P*
Cumulative response	N (%)	Median TTR, months (range)†	N (%)	Median TTR, months (range)†	P*
MCyR	441 (93)	2.9 (2-15)†	53 (98)	3.0 (3-24)†	.15
CCyR	429 (91)	3.1 (2-36)	47 (87)	3.1 (3-31)	.38
MMR	402 (85)	5.7 (2-74)	42 (78)	5.8 (3-76)	.16
MR^4.5	322 (68)	11.8 (3-145)	38 (70)	12.1 (3-136)	.73
BCR-ABL <10% at 3 mo	384 (81)	—	40 (74)	—	.21

Cumulative response	No ACAs (n = 473)		CCA/Ph⁻(n = 54)		P*
Cumulative response	N (%)	Median TTR, months (range)†	N (%)	Median TTR, months (range)†	P*
MCyR	441 (93)	2.9 (2-15)†	53 (98)	3.0 (3-24)†	.15
CCyR	429 (91)	3.1 (2-36)	47 (87)	3.1 (3-31)	.38
MMR	402 (85)	5.7 (2-74)	42 (78)	5.8 (3-76)	.16
MR^4.5	322 (68)	11.8 (3-145)	38 (70)	12.1 (3-136)	.73
BCR-ABL <10% at 3 mo	384 (81)	—	40 (74)	—	.21

P values shown are the results of comparing the corresponding response rates.

The only statistically significant difference in TTR was for MCyR with P = .01; the rest, not shown, were not significant.